Why Methotrexate Stands Out for Kids
Methotrexate is the first-line disease-modifying antirheumatic drug (DMARD) for juvenile idiopathic arthritis (JIA), the most common rheumatic disease in children, due to its strong efficacy, long safety track record, and oral or subcutaneous dosing options that suit pediatric needs.[1][2]
How It Compares to Alternatives Like Sulfasalazine or Leflunomide
In JIA trials, methotrexate achieves remission in 40-70% of patients within 6-12 months, outperforming sulfasalazine (effective mainly for enthesitis-related arthritis) and leflunomide (similar efficacy but higher liver enzyme elevations).[1][3] Guidelines from the American College of Rheumatology (ACR) and Pediatric Rheumatology European Society (PReS) recommend it over these for polyarticular JIA because it rapidly reduces joint inflammation and slows disease progression with fewer treatment switches.[2]
Safety Profile in Children vs. Adults
Children tolerate methotrexate better than adults, with nausea and mild liver issues resolving faster and lower malignancy risk over 10+ years of use. Weekly low doses (10-15 mg/m²) minimize toxicity compared to higher-dose cancer regimens.[1][4] Folic acid co-administration cuts side effects by 70-80%, making it safer than biologics like etanercept for initial therapy.[3]
Cost and Accessibility Edge
At $10-50 per month generically, methotrexate undercuts biologics (e.g., adalimumab at $1,000+/month), improving access in resource-limited settings. No refrigeration or complex infusions needed, unlike IV alternatives.2
When Biologics or Other DMARDs Take Over
Doctors switch from methotrexate if no response after 3-6 months (20-30% of cases), adding TNF inhibitors like etanercept. It's less favored in systemic JIA onset, where anakinra works faster.[1][3] Ongoing monitoring for cytopenias or infections remains key.
[1]: https://www.rheumatology.org/Portals/0/Files/JIA-Guideline-2021.pdf (ACR JIA Guidelines, 2021)
[2]: https://ard.bmj.com/content/77/6/829 (PReS/ACR JIA Treatment Recommendations, 2018)
[3]: https://pubmed.ncbi.nlm.nih.gov/24692525/ (Cochrane Review on MTX in JIA, 2014)
[4]: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641390/ (Long-term safety data in pediatrics, 2017)